



KIDS-BBK055-NSP

## Clinical Study Report

# A Clinical Study of 'GLUTANEX Night Serum' on the Improvement of Skin Clarity

Date : December 27, 2022

Requested by : Nexus Pharma Co., Ltd. (Korea)

Performed by : Korea Institute of Dermatological Sciences (Korea)



Korea Institute of  
Dermatological Sciences

# CERTIFICATE FOR RELIABILITY ASSURANCE



Title of the clinical study : A clinical study of 'GLUTANEX Night Serum' on the improvement of skin clarity

Case control No. : KIDS-BBK055-NSP

This study was conducted according to the regulations of designation as the test institution for drugs, quasi-drugs, cosmetics, and medical devices; the guidelines of the management standards for clinical drug evaluations; the guidelines of *in vivo* clinical and *in vitro* evaluation studies; the guidelines of the experimental methods for cosmetic display and advertisements; and the guidelines of the validation of functional cosmetics of the Ministry of Food and Drug Safety, Republic of Korea; the laws of the bioethics and safety of the Ministry of Health and Welfare, Republic of Korea; and the standard operation procedure of the Korea Institute of Dermatological Sciences. All procedures were investigated by the person in charge of reliability assurance.

Title of the clinical study	A clinical study of 'GLUTANEX Night Serum' on the improvement of skin clarity				
Date	Step	RA inspection categories	RA inspection result	Approval date	Note
November 21, 2022	Study plan	Reporting plan	Approved	November 21, 2022	
November 29, 2022~ December 13, 2022	Performing clinical trial	Reporting implementation	Approved	December 13, 2022	
December 14, 2022~ December 20, 2022	Analyzing data, Confirming the information on test product	Inspecting raw data	Approved	December 20, 2022	
December 21, 2022~ December 26, 2022	Report work	Inspecting draft report	Approved	December 26, 2022	
December 27, 2022	Report final report	Inspecting final report	Approved	December 27, 2022	

This report was prepared on the basis of the experiment results and accurately reflects the data.

December 27, 2022

Scientific Director In Sook An, Ph. D. (seal)

Reliability Assurance Ka Ram Kim, Ph. D. (seal)

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.

# SUMMARY OF THE CLINICAL STUDY



Title of the clinical study	A clinical study of 'GLUTANEX Night Serum' on the improvement of skin clarity	
Clinical trial institution	Korea Institute of Dermatological Sciences 6th Floor, Tower A, 25, Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Republic of Korea	
Sponsor	Nexus Pharma Co., Ltd.	
Chief researcher	In Sook An, Ph.D.	
Researcher	Seungbin Kwon, lil Hong, Yun Kim, Minji Jo, Sujeong Shin, Heemin Kwon, Jiyeon Kang, Sugyeong Hong, Hyunkyung Kim, Soyeon Park	
Name of the test material	GLUTANEX Night Serum	
Trial period	November 21, 2022 (Study initiation) ~ December 27, 2022 (Study termination) For the study initiation, the person in charge of the study signed the clinical study proposal; for the study termination, the person in charge of the study signed the final report.	
Trial period (Measurement period)	November 29, 2022 (First date of visit) ~ December 13, 2022 (End date of visit)	
Inclusion criteria	Female volunteers from twenty to sixty five years old with who met the inclusion criteria and were not included in the exclusion criteria were selected for this study.	
The age and number of subjects who completed the final study	Twenty two subjects from thirty four to sixty two (Average 48.00, Standard deviation 7.18) of female	
Methods	Usage of test product	Each subject applied the same amount of test material 'GLUTANEX Night Serum' evenly on the facial area and allowed it to be fully absorbed after cleansing twice a day, in the morning and the evening, during the two weeks test period.
Methods	Evaluations	The evaluations were conducted by Standard Operating Procedures of KIDS and all of the procedures were investigated by the person in charge of reliability assurance.  1. Measurements 1) Evaluation using SkinColorCatch and VISIA-CA to assess the skin clarity improvement

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.



Methods	Evaluations	2. Evaluation of abnormal skin response 3. Survey
Results	1. The evaluation results of skin clarity using SkinColorCatch and VISIA-CA The L* value indicating skin brightness was increased 0.97% after two weeks of the test material application in comparison with the pre-application ( $p < .001$ ).  2. Subjects' abnormal skin responses were not detected during the trial period.	
Conclusion	In the study requested by Nexus Pharma Co., Ltd., 'GLUTANEX Night Serum' was found to be helpful with improving skin clarity.	

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.